Who to believe?
In one corner, we have....- Otsuka
- Denner
- Blackrock
- Fidelity
- Other Tutes
- The FDA (giving AP26113 BTD)
- commercial agents throughout Europe, Eastern Europe, Asia (see above) and of course Australia
- Docs and patients who went to bat after the debacle
- Science (just peruse prior abstracts from publications about Pona, 113 etc....multiple indications, impact, efficacy...and, yes, learning how to manage the risk/benefit trade off).
- A logical plan about the strategy for growing the company, and a conservative scenario of $400m revenues in 3 years.
And in the other corner, we have...
- Daily bashers (shorts in long's clothing?)
- daily market fluctuations
- bitter investors that didn't sell when we were at 20+ (not that I can blame that, it's just them emotion clouds one's judgement).
So, who's your daddy?
GLTA
TC
TC, One would have to be increasingly curious as to why Sarrisa Capital Management has kept so quiet. After all, they are capable of making a nasty public scene very quickly. Here is a link concerning a previous negotiation that didn't go their way. http://www.marketwatch.com/story/sarissa-capital-issues-open-letter-regarding-astex-pharmaceuticals-2013-10-02
ReplyDelete